Delivering on the Potential of Biosimilar Medicines

As biologic medicines play a more significant role in patient care across a growing number of disease areas, the emergence of biosimilar medicines across Europe and in the United States brings the promise of new sources of value.

Spotlight

Viralytics Limited

Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). It is being evaluated in Phase 1 and 2 clinical trials in various treatment settings against a range of cancer indications.

OTHER WHITEPAPERS
news image

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

Read More
news image

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

Read More
news image

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More
news image

Biocontamination control in pharmaceutical production

whitePaper | November 11, 2022

Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.

Read More
news image

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Read More
news image

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More

Spotlight

Viralytics Limited

Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). It is being evaluated in Phase 1 and 2 clinical trials in various treatment settings against a range of cancer indications.

Events